495 related articles for article (PubMed ID: 19171174)
1. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study.
Vila-Corcoles A; Salsench E; Rodriguez-Blanco T; Ochoa-Gondar O; de Diego C; Valdivieso A; Hospital I; Gomez-Bertomeu F; Raga X
Vaccine; 2009 Mar; 27(10):1504-10. PubMed ID: 19171174
[TBL] [Abstract][Full Text] [Related]
2. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study.
Vila-Córcoles A; Ochoa-Gondar O; Hospital I; Ansa X; Vilanova A; Rodríguez T; Llor C;
Clin Infect Dis; 2006 Oct; 43(7):860-8. PubMed ID: 16941367
[TBL] [Abstract][Full Text] [Related]
3. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in patients with chronic pulmonary diseases: a matched case-control study.
Vila-Corcoles A; Ochoa-Gondar O; Rodriguez-Blanco T; Gutierrez-Perez A; Vila-Rovira A;
Hum Vaccin Immunother; 2012 May; 8(5):639-44. PubMed ID: 22634442
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older.
Vila-Corcoles A; Ochoa-Gondar O; Guzmán JA; Rodriguez-Blanco T; Salsench E; Fuentes CM;
BMC Infect Dis; 2010 Mar; 10():73. PubMed ID: 20298596
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of pneumococcal polysaccharide vaccine in older adults.
Jackson LA; Neuzil KM; Yu O; Benson P; Barlow WE; Adams AL; Hanson CA; Mahoney LD; Shay DK; Thompson WW;
N Engl J Med; 2003 May; 348(18):1747-55. PubMed ID: 12724480
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of pneumococcal vaccination for elderly people in Catalonia, Spain: a case-control study.
Dominguez A; Salleras L; Fedson DS; Izquierdo C; Ruiz L; Ciruela P; Fenoll A; Casal J
Clin Infect Dis; 2005 May; 40(9):1250-7. PubMed ID: 15825026
[TBL] [Abstract][Full Text] [Related]
7. Effect of pneumococcal vaccination: a comparison of vaccination rates in patients with bacteremic and nonbacteremic pneumococcal pneumonia.
Musher DM; Rueda-Jaimes AM; Graviss EA; Rodriguez-Barradas MC
Clin Infect Dis; 2006 Oct; 43(8):1004-8. PubMed ID: 16983612
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case-control study.
Peñaranda M; Falco V; Payeras A; Jordano Q; Curran A; Pareja A; Samperiz G; Dalmau D; Ribera E; Riera M
Clin Infect Dis; 2007 Oct; 45(7):e82-7. PubMed ID: 17806042
[TBL] [Abstract][Full Text] [Related]
9. Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study.
Farr BM; Johnston BL; Cobb DK; Fisch MJ; Germanson TP; Adal KA; Anglim AM
Arch Intern Med; 1995 Nov; 155(21):2336-40. PubMed ID: 7487259
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of the 23-valent polysaccharide vaccine against invasive pneumococcal disease in Navajo adults.
Benin AL; O'Brien KL; Watt JP; Reid R; Zell ER; Katz S; Donaldson C; Parkinson A; Schuchat A; Santosham M; Whitney CG
J Infect Dis; 2003 Jul; 188(1):81-9. PubMed ID: 12825175
[TBL] [Abstract][Full Text] [Related]
11. Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects.
Vila-Córcoles A; Ochoa-Gondar O; Llor C; Hospital I; Rodríguez T; Gómez A
Eur Respir J; 2005 Dec; 26(6):1086-91. PubMed ID: 16319340
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-based case-control study.
Barricarte A; Castilla J; Gil-Setas A; Torroba L; Navarro-Alonso JA; Irisarri F; Arriazu M
Clin Infect Dis; 2007 Jun; 44(11):1436-41. PubMed ID: 17479939
[TBL] [Abstract][Full Text] [Related]
13. Pneumococcal vaccine in the prevention of community-acquired pneumonia: a skeptical view of cost-effectiveness.
Simberkoff MS
Semin Respir Infect; 1993 Dec; 8(4):294-9. PubMed ID: 7938926
[TBL] [Abstract][Full Text] [Related]
14. Impact of pediatric vaccination with pneumococcal conjugate vaccine on the risk of bacteremic pneumococcal pneumonia in adults.
Metlay JP; Fishman NO; Joffe M; Edelstein PH
Vaccine; 2006 Jan; 24(4):468-75. PubMed ID: 16125826
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study.
Ochoa-Gondar O; Vila-Corcoles A; Rodriguez-Blanco T; Gomez-Bertomeu F; Figuerola-Massana E; Raga-Luria X; Hospital-Guardiola I
Clin Infect Dis; 2014 Apr; 58(7):909-17. PubMed ID: 24532544
[TBL] [Abstract][Full Text] [Related]
16. An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting.
Mangtani P; Roberts JA; Hall AJ; Cutts FT
Int J Epidemiol; 2005 Jun; 34(3):565-74. PubMed ID: 15764694
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly.
Domínguez A; Izquierdo C; Salleras L; Ruiz L; Sousa D; Bayas JM; Nebot M; Varona W; Celorrio JM; Carratalà J;
Eur Respir J; 2010 Sep; 36(3):608-14. PubMed ID: 20075048
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged ≥65 years: a retrospective case-control study.
Leventer-Roberts M; Feldman BS; Brufman I; Cohen-Stavi CJ; Hoshen M; Balicer RD
Clin Infect Dis; 2015 May; 60(10):1472-80. PubMed ID: 25669354
[TBL] [Abstract][Full Text] [Related]
19. Pneumococcal vaccination in the prevention of community-acquired pneumonia: an optimistic view of cost-effectiveness.
Fedson DS
Semin Respir Infect; 1993 Dec; 8(4):285-93. PubMed ID: 7938925
[TBL] [Abstract][Full Text] [Related]
20. Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia.
Johnstone J; Eurich DT; Minhas JK; Marrie TJ; Majumdar SR
Clin Infect Dis; 2010 Jul; 51(1):15-22. PubMed ID: 20504233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
